Loading
A phase 3 trial testing JSKN003 in HER2-positive breast cancer, now recruiting.
JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer is a phase 3 interventional study registered as NCT06846437, led by Shanghai JMT-Bio, and recruiting on the registry. Official title: A Randomised, Controlled, Open-Label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer Subjects. Planned enrolment is 228 participants (estimated). The study started in 2025-02-18 and primary completion is expected in 2026-10-13. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares CSPC Pharmaceutical Group, HER2-positive breast cancer.
Shares CSPC Pharmaceutical Group, HER2-positive breast cancer.
Shares CSPC Pharmaceutical Group, HER2-positive breast cancer.
Shares CSPC Pharmaceutical Group, HER2-positive breast cancer.
Shares CSPC Pharmaceutical Group, HER2-positive breast cancer.
Shares CSPC Pharmaceutical Group, HER2-positive breast cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/